Specifically, its utility in distinguishing early-stage groups (pre-AD and MCI-AD) is evident from studies applying the A/T/N classification scheme (amyloid (A), tau (T), and neurodegeneration (N)) [111]. The gene discussed is MAPT; the disease is Alzheimer disease.